Carman Alenson - 21 Feb 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
SVP, Finance and Chief Accounting Officer
Signature
/s/ Karen Brown, attorney-in-fact
Issuer symbol
PRME
Transactions as of
21 Feb 2024
Net transactions value
$0
Form type
4
Filing time
23 Feb 2024, 17:01:25 UTC
Previous filing
20 Apr 2023
Next filing
03 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +90,498 $0.000000 90,498 21 Feb 2024 Common Stock 90,498 $8.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

SVP, Finance and Chief Accounting Officer